Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche’s Polivy Set For Blockbuster Sales After Frontline Lymphoma Success

First Progress In Frontline DLBCL In 20 Years

Executive Summary

Roche has not disclosed the full data yet, but is confident that Polivy can surpass CAR-Ts and other competitors to be the new standard of care.

You may also be interested in...

Roche’s Polivy Wins US Approval In Untreated Lymphoma But Blockbuster Potential Uncertain

The firm’s antibody-drug conjugate plus Rituxan and R-CHP chemoimmunotherapy has won a US thumbs up for first-line diffuse large B-cell lymphoma but lingering concerns about magnitude of benefit could lead to limited uptake.

Roche Plays Down Reliance On TIGIT And Alzheimer’s Drugs For Growth

Pharma chief Bill Anderson was optimistic about growth prospects, and downplayed Roche’s reliance on two near-term readouts at an investor day in London.

New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC

Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts